• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to new 6- or 7-methylenandrosta-1,4-diene-3,17-diones of the following formula <CHEM> wherein R is hydrogen or fluorine; R1 is hydrogen or C1-C6 alkyl; R2 is hydrogen or halogen; one of R3 and R4 is =CH2 and the other is hydrogen or C1-C4 alkyl, and when R3 is =CH2, at least one of R and R4 is other than hydrogen; and the symbol @ @@ represents a double bond and the symbol @@@ represents a single bond when R3 is =CH2 or the symbol @@@ represents a single bond and the symbol @@@ represents a double bond when R4 is =CH2, which are useful in therapy, in particular as anti-cancer agents.
    公开号:SU1549485A3
    申请号:SU874202950
    申请日:1987-07-13
    公开日:1990-03-07
    发明作者:Буццетти Франко；Барбуджан Натале；Ломбарди Паоло；Ди Салле Энрико
    申请人:Фармиталиа Карло Эрба С.Р.Л. (Фирма)；
    IPC主号:
    专利说明:


    s
    This invention relates to a process for the preparation of new derivatives 6 of methylene-androst-1, 4-diene-3, 17-dione of the general formula
    Ri
    ABOUT
     .
    where R ,, is hydrogen or alkyl;
    Ra - C-C-alkyl,
    having pharmacological properties.
    The purpose of the invention is to obtain new derivatives of androsta-1,4-diene of 3,17-dione, which are able to inhibit aromatism to a greater degree in comparison with known structural analogues.
    Example 1. A mixture of sodium acetate (lg), chloroform (30 ml), diethyl acetal formaldehyde (30 ml, 0.24 mol), phosphoryl chloride (3.8 ml, 0.04 mol) and 1.7 ° di methylandrost-4 ene-3,17-dione (0.849 ge 2.7 mmol) is stirred at boiling point for 5 hours, i.e. until the original substance disappears. The suspension is cooled and a saturated solution of sodium carbonate is added dropwise with vigorous stirring until the pH of the aqueous layer is alkaline. The organic layer is separated, washed to neutrality and dried over sodium sulfate. After concentration under reduced pressure, the oily residue is purified by silica gel chromatography using a mixture of hexane and ethyl acetate as eluent. Thus, a pure 1 / 3,7sЈ-dimesht 6-methylenandrost-4-ene-3,1 7-dione is obtained in 60% yield (0.530 g /
    0.530 g of 1Ј, 7 ° (-dimesht-6-methylene-androst-4-en-3, 17-dione and 0.59 g of dichlorodianbenzoquinone are heated under reflux in 20 ml of anhydrous dioxane. About 15 h. The reacting mixture is filtered, the solvent is removed in vacuo, the residue is dissolved in ethyl acetate, the organic layer is washed with water, dried over sodium sulfate and the solvent is evaporated in vacuo. The crude product is subjected to silica gel chromatography using 40% mixture of hexane and ethyl acetate as eluent, which gives 0, 42 g of pure 1, 7c-dimethyl-6-methylenandrost-1,4-diene-3, 17 -dione.
    five
    0
    five
    0

    Q
    five
    0
    five
    five
    Found,%: C 81.35; H 38.09.
    Sea N e80g
    Calculated,%: C 81, 44; H 28.22.
    NMR, ppm: 0.90 (ZN.d); 0.93 (3N, s); 1.15 (ЗН, s); 2.3 (ZN, br. S)) 4.98 (2H, m); 6.10 (1H, d); 6.25 (1H, d); 7.10 (1H, d).
    IR spectrum, (KVg), 3080 (-CH); 1730 (17-oxo); 1650 (3-oxo), 1620, 1590 (conjugation: double bonds).
    Mass Spectrum (m / z) 324.
    According to the described procedure and starting from the corresponding compound, 7-methyl-6-methylene-androst-1,4-diene-3, 17-dione can be obtained.
    NMR, ppm: 0.91 (ZN, d); 0.94 (3N, s); 1.16 (3N, s) ;, 4.97 (2H, m); 6.14 (1H, d); 6.27 (1H, d); 7.08 (1H, d). I
    IR spectrum, (KBG), cm 1: 3070 (CHt); 1735 (17-oxo); 1655 (3-oxo); 1625, 1595 (conjugation: double bonds). Mass Spectrum 330. Example 2. Tablets each weighing 0.150 g each and containing 25 mg of active substance are manufactured as follows.
    The composition (for 10,000 tablets), g: 7o (-Methes1-6 methylene-androsta-1,4-diene-3,17-dione252
    Lactose 800
    Corn starch 415 Talcum powder30
    Magnesium stearate 5
    7 ° (α-methyl-6-methylene growth-1,4-diene-3, 17-dione, lactose, half of corn starch are mixed. The mixture is passed through a 0.5 mm mesh sieve. Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, crushed on a 1.4 mm mesh sieve, then the remaining amount of starch, talc and magnesium stearate is added, mixed thoroughly and tablets are made.
    Example 3. Capsules of 0.2000 g each and containing 20 mg of the active substance are prepared as follows.
    The composition for 500 capsules, g: 7o (-Me of ti-6-methyl n-androsta-1,4-dien-3, 17-dione O
    Lactose80
    Corn Starch 5
    Magnesium stearate 5
    This formulation is enclosed in a capsule consisting of two hard gelatin capsules with a dose of 0.200 g each capsule.
    The proposed compounds are inhibitors of the biotransformation of male sex hormones into folliculin, i.e. they are steroid aromatase inhibitors.
    Aromatase inhibition by the proposed compounds was determined, for example, in vivo (ovarian aromatae activity) in rats. The activity of the proposed compounds: 7-methyl-6-methylene-androsta-1,4-diene-1,17-dione and 1,3-dimethyl-6-methylene-androsta-1,4-diene-1,17-dione, is compared with the activity well known aromatase inhibitor, 4-hydroxyandrost-4-ene 3,17-dione and with the activity of 7oЈ-methyl-6-methylene-1,2-cyclopropanoandrost-4-ene-3,17-dione in accordance with the following procedure.
    Adult female rats were twice treated subcutaneously using 100 international units of pregnant mare's serum gonadotropin (PMSG) at a 4-day interval in order to increase the activity of ovarian aromatase in accordance with the Brodie technique. Three days after the second treatment with PMSG, a group of 6 animals were each given an oral carrier (0.5% methylcellulose) or an inhibitor in an amount of 30 mg / kg. Animals were killed after 24 hours, microsomes were isolated from the ovaries and their aromatase activity was determined using a method similar to that described.
    Incubations were performed for 30 minutes in a 1 ml incubation volume containing 0.1 mg of microsomal proteins, 100 nM 4-4H androstenedione and 100 µM WADPH. The% inhibition of the control aromatase activity was then calculated.
    In vivo aromatase inhibition of rat ovary is shown in the table.
    Because of their ability to inhibit aromatase and, therefore, reduce estrogen levels, new compounds are useful in treating and preventing various estrogen-related diseases, i.e. endometrial, ovarian and pancreatic breast cancers, gynecomastia,
    ten
    15
    20
    25

    5494856
    benign mammary gland tumor, endometriosis, polycystic ovarian disease and precocious puberty. Another use of the compounds of the invention is the therapeutic and / or prophylactic treatment of prostatic hyperplasia, an estrogen-dependent stromal tissue disease. New compounds may also be used for long. treatment of male infertility associated with oligospermia, and to regulate female fertility, because of their ability to inhibit ovulation and nidation of the egg cell.
    In view of their high therapeutic index, the proposed compounds can be used safely in medicine. For example, the approximate acute toxicity (LDjo) of the compounds proposed in a mouse, determined by a single injection of increasing dosages and measured on the seventh day after treatment, is an insignificant amount.
    For example, the LD50 value for the proposed compounds: 7-methyl-6-methylene-1, 4-diene-3,1 7-dione and 1, 7 ° (-dimethyl-6-methylene-1,4-diene -3, 17-dione is above 800 mg / kg when orally administered to the mouse.
    thirty
    权利要求:
    Claims (1)
    [1]
    The invention The method of obtaining derivatives of 6-methylenandrost-1,4-diene-3, 17-dione of the general formula
    And, Ш °
    where R ,, is hydrogen or C -C-alkyl;
    RO. - C, -C-alkyl, characterized in that the compounds of the general formula are dehydrogenated
    Rl
    where R and Ra have the indicated meanings by treating with a dehydrating agent to the compound.
    4-Hydro Siandro St4-en-3, 17-Dione7
    7aC-Methyl-6-methylene1,2-cyclopropanandrost-4-en-3, 17dione23
    7-Methyl-6-methylene1, 4-dien-3, I7-dione 71
    1, 7p (-Dimethyl-6-methylene-1, 4-diene-3, 17dione40
    solvent at reflux temperature.
    Inhibition of aromatase at 30 mg / kg, orally,
    类似技术:
    公开号 | 公开日 | 专利标题
    US4808616A|1989-02-28|6-substituted androsta-1,4-diene-3,17-diones
    SU1549485A3|1990-03-07|Method of producing derivatives of 6-methyleneandrosta-1,4-diene-3,17-dione
    GB2171100A|1986-08-20|4-substituted androstendione derivatives and process for their preparation
    EP0260975B1|1989-07-19|4-substituted 6- alkylidenandrostene-3,17-dione derivatives and process for their preparation
    IE48076B1|1984-09-19|Steroid 2-carbonitriles
    US5486511A|1996-01-23|4-amino-17β-|androst-4-en-3-one, 4-amino-17β-|androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
    SU1639428A3|1991-03-30|Method for preparation of 4=cycloalkylsubstituted pyridine derivatives or theirs hydrochlorides
    US6087347A|2000-07-11|3-substituted-D-homo-1,3,5|-estratriene derivatives
    CA2361168A1|2000-07-27|Steroid sulfatase inhibitors and methods for making and using the same
    AU592878B2|1990-01-25|New androst-4-ene-3,17-diones and process for their preparation
    EP0469547B1|1996-05-15|4-Amino-delta4,6-steroids and their use as 5alpha-reductase inhibitors
    KR100227717B1|1999-11-01|C17-20 lyase inhibiting pharmaceutical composition
    US4771043A|1988-09-13|Steroidic aromatase inhibitors
    EP0742214A1|1996-11-13|Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same
    US5126488A|1992-06-30|2β,19-methyleneamino bridged steroids as aromatase inhibitors
    US5457097A|1995-10-10|Androst-4-eno[4,5-b]pyrrole derivatives
    JPH08500609A|1996-01-23|Fluorinated 6-methyleneandrosta-1,4-dien-3-one derivative and method for producing the derivative
    Weintraub et al.1996|4-Amino-17β-| androst-4-en-3-one, 4-Amino-17β-| androst-4-en-3-one and Related Compounds as C17, 20-Lyase and 5α-Reductase Inhibitors
    EP0620823A1|1994-10-26|6,7$g|-DIFLUOROMETHYLENANDROSTA-1,4-DIEN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
    GB2195639A|1988-04-13|Polyconjugated androstenediones and process for their preparation
    同族专利:
    公开号 | 公开日
    AU589269B2|1989-10-05|
    GB8617107D0|1986-08-20|
    NZ221012A|1989-05-29|
    IL83132A|1992-01-15|
    DE3760277D1|1989-08-03|
    ZA875098B|1988-03-30|
    EP0253591B1|1989-06-28|
    FI873052A|1988-01-15|
    JP2643943B2|1997-08-25|
    JPS6323895A|1988-02-01|
    US4824830A|1989-04-25|
    ES2010513B3|1989-11-16|
    CA1309400C|1992-10-27|
    MY100512A|1990-10-30|
    EP0253591A1|1988-01-20|
    CN87104750A|1988-03-23|
    YU129487A|1988-10-31|
    YU45827B|1992-07-20|
    DK364787D0|1987-07-13|
    FI873052A0|1987-07-10|
    HU196223B|1988-10-28|
    DK364787A|1988-01-15|
    PT85318B|1990-04-30|
    CS535087A2|1988-08-16|
    AU7550887A|1988-01-21|
    HUT44038A|1988-01-28|
    NO872892D0|1987-07-10|
    AT44282T|1989-07-15|
    GR3000085T3|1990-10-31|
    PH22994A|1989-02-24|
    PT85318A|1987-08-01|
    IL83132D0|1987-12-31|
    CS262695B2|1989-03-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB929985A|
    US2744120A|1953-01-14|1956-05-01|Olin Mathieson|1-dehydrotestololactone|
    US4235893A|1978-05-08|1980-11-25|Brodie Angela M|Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis|
    DE3322285A1|1983-06-18|1984-12-20|Schering AG, 1000 Berlin und 4709 Bergkamen|1-ALKYL-ANDROSTA-1,4-DIEN-3,17-DIONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM|
    DE3485093D1|1984-12-28|1991-10-24|Ibm|BREEDING METHOD AND DEVICE FOR PRODUCING SILICON CRYSTALS WITH A HIGH AND CONTROLLED CARBON CONTENT.|
    GB8517360D0|1985-07-09|1985-08-14|Erba Farmitalia|Substituted androsta-1,4-diene-3,17-diones|
    JPH0718729B2|1990-06-11|1995-03-06|山武ハネウエル株式会社|Heater temperature control circuit|US5719448A|1989-03-07|1998-02-17|Seiko Epson Corporation|Bonding pad structures for semiconductor integrated circuits|
    US5227375A|1990-02-08|1993-07-13|Endorecherche, Inc.|Aromatase inhibitors|
    JP2602456B2|1990-04-12|1997-04-23|雪印乳業株式会社|Endometriosis treatment|
    CH683151A5|1991-04-24|1994-01-31|Ciba Geigy Ag|Contraception in female primates without affecting the menstrual cycle.|
    GB9217035D0|1992-08-11|1992-09-23|Erba Carlo Spa|Androst-4-enopyrrole derivatives and process for their preparation|
    CA2118317A1|1993-02-18|1994-09-01|Pharmacia S.P.A.|Fluorinated 4-aminoandrostadienone derivatives and process for their preparation|
    GB9313420D0|1993-06-29|1993-08-11|Erba Carlo Spa|Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations|
    FI109641B|2000-03-10|2002-09-13|Nokia Corp|microphone structure|
    US20040082557A1|2001-01-26|2004-04-29|Wajszczuk Charles Paul|Methods for treating estrogen-dependent disorders|
    AT337787T|2001-01-26|2006-09-15|Pfizer Italia Srl|EXEMESTAN FOR THE TREATMENT OF HORMONE-RELATED DISORDER|
    US20050101581A1|2002-08-28|2005-05-12|Reading Christopher L.|Therapeutic treatment methods 2|
    US8183401B2|2004-01-16|2012-05-22|Cedarburg Pharmaceuticals, Inc.|Exemestane and its intermediates and methods of making the same|
    US20080275259A1|2007-05-04|2008-11-06|Scinopharm Taiwan, Ltd|Process for preparing aromatase inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB868617107A|GB8617107D0|1986-07-14|1986-07-14|6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives|
    [返回顶部]